CONCERT PHARMACEUTICALS INC's ticker is CNCE and the CUSIP is 206022105. A total of 102 filers reported holding CONCERT PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $1,198,000 | -15.9% | 366,448 | +8.6% | 0.01% | -20.0% |
| Q2 2021 | $1,424,000 | +148.1% | 337,436 | +193.6% | 0.01% | +150.0% |
| Q1 2021 | $574,000 | -76.8% | 114,932 | -41.3% | 0.00% | -81.8% |
| Q4 2020 | $2,475,000 | +27.6% | 195,800 | -0.8% | 0.02% | +10.0% |
| Q3 2020 | $1,939,000 | -15.7% | 197,434 | -14.6% | 0.02% | -20.0% |
| Q2 2020 | $2,301,000 | +8.4% | 231,260 | -3.7% | 0.02% | -7.4% |
| Q1 2020 | $2,123,000 | +6.1% | 240,207 | +10.7% | 0.03% | +35.0% |
| Q4 2019 | $2,001,000 | +294.7% | 216,912 | +151.3% | 0.02% | +233.3% |
| Q3 2019 | $507,000 | +7.4% | 86,300 | +119.6% | 0.01% | -14.3% |
| Q2 2019 | $472,000 | -21.3% | 39,300 | -32.6% | 0.01% | -41.7% |
| Q4 2016 | $600,000 | +86.3% | 58,314 | +83.1% | 0.01% | +100.0% |
| Q3 2016 | $322,000 | +7.0% | 31,852 | +18.7% | 0.01% | 0.0% |
| Q2 2016 | $301,000 | +85.8% | 26,836 | +126.7% | 0.01% | +100.0% |
| Q1 2016 | $162,000 | – | 11,840 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| L1 Capital Pty Ltd | 968,198 | $9,634,000 | 3.29% |
| INGALLS & SNYDER LLC | 1,382,048 | $13,751,000 | 0.79% |
| SPHERA FUNDS MANAGEMENT LTD. | 700,710 | $6,972,000 | 0.66% |
| Alambic Investment Management, L.P. | 17,900 | $178,000 | 0.45% |
| RA Capital Management | 1,858,474 | $18,492,000 | 0.36% |
| Perceptive Advisors | 2,150,641 | $21,398,000 | 0.35% |
| Eversept Partners, LP | 232,983 | $2,318,181 | 0.32% |
| GSA CAPITAL PARTNERS LLP | 17,351 | $173,000 | 0.10% |
| Alyeska Investment Group, L.P. | 502,783 | $5,003,000 | 0.08% |
| KENNEDY CAPITAL MANAGEMENT LLC | 263,958 | $2,626,000 | 0.08% |